1. Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
- Author
-
Dang, Nana, Lin, Yuan, Waer, Mark, and Sprangers, Ben
- Subjects
- *
TUMOR antigens , *FLUOROURACIL , *MAJOR histocompatibility complex , *LYMPH nodes , *MELANOMA , *DENDRITIC cells , *RESEARCH , *IMMUNOGLOBULINS , *IMMUNIZATION , *ANIMAL experimentation , *RESEARCH methodology , *LUNG tumors , *ANTINEOPLASTIC agents , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *CELL lines , *MICE , *PHARMACODYNAMICS - Abstract
Alloantibodies, in particular immunoglobulin G (allo-IgG), confer a rejection advantage to tumors sharing the same major histocompatibility complex (MHC) in mice. However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation. Here, we developed high titer allo-IgG by multiple rounds of immunization with allogenic B16 melanoma cells, which allows for the strong binding with B16 cells. We demonstrate that B16 cells incubated with these allo-IgG (referred to as allo-IgG-B16) become highly immunogenic, which release tumor antigens that are efficiently presented by classic DCs in lymph nodes (LNs). Injection of allo-IgG-B16 turns the tumor into an immune hot one and even elicits a systemic antitumor response when used together with 5-fluorouracil (5-FU). This systemic response is tumor-specific and relies on the critical site - LNs. Our findings provide a rationale for the use of allo-IgG in cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF